A signal, not proof—yet.
En los márgenes de una investigación diseñada para tratar la diabetes y la obesidad, los científicos han comenzado a vislumbrar algo inesperado: que ciertos medicamentos podrían alterar el curso del cáncer. Los fármacos GLP-1, conocidos por marcas como Ozempic y Mounjaro, muestran en estudios observacionales una correlación con menores tasas de progresión tumoral y mayor supervivencia en pacientes con cáncer de mama y pulmón. La ciencia, sin embargo, recuerda su propia disciplina: observar un patrón no es lo mismo que comprender su causa, y el camino entre la promesa y la certeza exige aún la prueba más rigurosa.
- Los datos son llamativos: mujeres con cáncer de mama que usaron GLP-1 progresaron a un 10%, frente al 20% de quienes no los tomaron, y más del 95% sobrevivieron cinco años.
- Un estudio con casi 95,000 mujeres halló un 25% menos de riesgo de diagnóstico de cáncer de mama entre usuarias de GLP-1, incluso controlando por edad y peso corporal.
- El patrón se repite en el cáncer de pulmón, donde la progresión a etapas avanzadas fue del 10% en usuarios frente al 22% en no usuarios, sugiriendo un efecto sistémico aún sin explicar.
- La comunidad científica advierte que la evidencia es observacional y que factores como hábitos de vida o acceso a mejor atención médica podrían distorsionar los resultados.
- Antes de recomendar estos fármacos para prevención oncológica, los investigadores exigen ensayos clínicos aleatorizados que establezcan causalidad real, no solo correlación.
Una clase de medicamentos creada para tratar la diabetes y la obesidad está mostrando una conexión inesperada con los resultados oncológicos. Los fármacos GLP-1, entre ellos Ozempic, Mounjaro y Wegovy, regulan el azúcar en sangre y suprimen el apetito, pero investigaciones recientes sugieren que su alcance podría ir mucho más allá.
En cáncer de mama, los números resultan notables. Las mujeres que usaban estos medicamentos progresaron en un 10%, frente al 20% de quienes no los tomaban. Tras cinco años de seguimiento, más del 95% de las pacientes tratadas seguían con vida, en comparación con el 89,5% del grupo sin tratamiento, según datos del MD Anderson Cancer Center. Un estudio separado de la Universidad de Pensilvania, que analizó a casi 95,000 mujeres, encontró un 25% menos de riesgo de diagnóstico de cáncer de mama entre usuarias de GLP-1, una reducción que se mantuvo incluso al controlar por edad y peso.
En cáncer de pulmón se observó un patrón similar: progresión a etapas avanzadas del 10% entre usuarios, frente al 22% en no usuarios. La consistencia entre distintos tipos de cáncer apunta a algo sistémico, aunque su mecanismo permanece sin descifrar. El hecho de que la protección persista independientemente del peso sugiere que los fármacos podrían estar interfiriendo con el crecimiento tumoral a través de vías celulares aún desconocidas.
Sin embargo, la advertencia es fundamental: toda la evidencia disponible es observacional. Los investigadores no pueden descartar que otros factores —mejores hábitos de vida, mayor acceso a atención médica— expliquen parte de la correlación. Para establecer causalidad real se necesitan ensayos clínicos aleatorizados. Hasta entonces, estos hallazgos representan una puerta entreabierta hacia una posibilidad, no una ruta confirmada.
A class of drugs developed to treat diabetes and obesity is showing an unexpected connection to cancer outcomes in early research. Medications like Ozempic and Mounjaro, which work by regulating blood sugar and suppressing appetite, appear to correlate with slower tumor growth and better survival rates in certain cancers—though researchers are careful to note that correlation is not yet proof of cause and effect.
These GLP-1 agonists function by helping the body manage glucose levels in people with type 2 diabetes. Some versions also treat obesity. They're administered as injections into the fatty tissue beneath the skin—typically in the abdomen, outer thigh, upper buttock, or back of the arm. The drugs, which include Ozempic, Mounjaro, Trulicity, Victoza, Wegovy, and Zepbound, have earned a reputation for effectiveness in weight loss and for reducing cardiovascular risk. But recent findings suggest their reach may extend further.
In breast cancer specifically, the numbers are striking. Among women using these medications, the rate of cancer progression stood at 10 percent, compared to 20 percent among those who did not use them. After five years of follow-up, more than 95 percent of women with breast cancer who took these drugs remained alive, versus 89.5 percent of those who did not receive the treatment, according to research from MD Anderson Cancer Center at the University of Texas.
A separate study from the University of Pennsylvania examined nearly 95,000 women who underwent mammography screening. Those who had received at least one dose of a GLP-1 agonist showed a 25 percent lower risk of a breast cancer diagnosis—a reduction that held even when researchers controlled for age and weight. This finding suggests the drugs may offer protective benefits beyond simple weight loss or blood sugar control. The research, published in JAMA Network Open, proposes that these medications could improve survival odds and reduce recurrence risk in some breast cancer patients through mechanisms not yet fully understood.
Lung cancer patients showed a similar pattern. Those using these medications experienced disease progression to advanced stages at a rate of 10 percent, compared to 22 percent among non-users. The consistency across cancer types hints at something systemic at work, though what exactly remains unclear.
Here lies the critical caveat: the research community has not yet conducted the randomized controlled trials necessary to prove that these drugs directly cause the improved outcomes. The current evidence is observational—researchers have noticed patterns in patient data, but they cannot yet rule out other factors that might explain the correlation. A patient who takes Ozempic for diabetes might also exercise more, eat better, or have access to superior cancer care. Those variables cloud the picture.
Obesity itself is known to worsen breast cancer outcomes, particularly in postmenopausal women, because excess fat tissue can fuel tumor growth. Weight loss alone might account for some of the benefit. But the Pennsylvania study's finding that protection persisted independent of weight suggests something more is happening at the cellular level. The drugs may be interfering with cancer growth through pathways that have nothing to do with appetite or glucose.
Before these medications can be recommended for cancer prevention or treatment, researchers say they need properly designed clinical trials—studies where some patients receive the drug and others receive a placebo, with neither group nor researchers knowing who got what. Only then can causality be established. Until that evidence arrives, the current findings remain intriguing but incomplete: a door opening onto a possibility, not yet a proven path forward.
Notable Quotes
These medications may offer protective benefits beyond simple weight loss or blood sugar control, though causality has not yet been established.— Researchers citing JAMA Network Open findings
Randomized controlled trials are needed before these drugs can be recommended for cancer prevention or treatment.— Medical research community consensus
The Hearth Conversation Another angle on the story
Why would a diabetes drug affect cancer at all? They seem unrelated.
Obesity and high blood sugar both create an environment where cancer cells thrive. These drugs address both. But the real mystery is whether they're just helping by reducing weight, or if something about the drug itself—the way it works on cells—is slowing tumors.
The numbers look pretty convincing. Ten percent progression versus twenty percent.
They do. But that's observational data. You're comparing people who chose to take the drug with people who didn't. Those groups might differ in ways we can't measure—discipline, access to care, genetics. The numbers are a signal, not proof.
So what would proof look like?
A randomized trial. You give half the patients the drug, half a placebo. Nobody knows who got what. Then you follow them and see if the drug group actually does better. That's the only way to separate the drug's effect from everything else.
How long would that take?
Years. Maybe many years. These are cancer patients. You need long follow-up to know if someone truly survived longer. That's why we're still waiting.